Technology
Cancer treatment facilities face ongoing drug shortages, complicating patient care and raising concerns over long-term impacts on treatment efficacy.
Technology
FDA has approved an advanced AI tool to improve triage for heart attack patients, enhancing care during critical events.
Finance
Recent failures of cardiovascular drugs from Novartis and Novo Nordisk may hinder the industry's efforts in Lp(a) treatments.
Sports
To counteract vaccine hesitancy, the pro-vaccine movement must reignite enthusiasm and communal spirit, incorporating joy and engagement into advocacy.
Finance
The Trump administration plans to issue $500 refund checks to nearly 1 million ACA enrollees without federal subsidies, targeting key swing states prior to elections.
Finance
A recent study reveals the long-term impact of platinum-based chemotherapy on DNA mutations in children, raising concerns for future cancer risks.
Finance
The FDA has suspended Shoolin Pharma's product shipments to the U.S. due to unsanitary conditions and incomplete testing records found during an inspection.
Finance
UnitedHealth's financial support for Rep. Katherine Clark raises questions about its impact on healthcare legislation amid ongoing billing debates.
Technology
Oura reveals impressive earnings of $1.2 billion as it prepares for a public offering, positioning itself strongly in the consumer health tech space.
Technology
AstraZeneca has gained FDA approval for its latest breast cancer medication, marking a significant milestone in oncology treatment.
Finance
Novartis and Novo Nordisk encounter significant trial failures, raising concerns about their drug development strategies and future pipeline viability.
Technology
AstraZeneca's tozorakimab has significantly reduced COPD flare-ups in late-stage trials, hinting at its potential as a leading treatment option.
Technology
Inhibrx reports promising results from its OX40-targeted immunotherapy, especially in HPV-positive head and neck cancer patients, marking a notable industry breakthrough.
Technology
Roivant's experimental drug, mosliciguat, demonstrates significant efficacy in a mid-stage trial for pulmonary hypertension, signaling potential new treatment avenues.
Technology
The Phase 3 trial for Novartis' cardiovascular drug pelacarsen concluded without significant results, impacting its potential in heart disease treatment.